ACIPHEX Drug Patent Profile

When do Aciphex patents expire, and what generic alternatives are available?

Aciphex is a drug marketed by Waylis Therap and Aytu and is included in two NDAs.

The generic ingredient in ACIPHEX is rabeprazole sodium. There are thirty drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the rabeprazole sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Aciphex

A generic version of ACIPHEX was approved as rabeprazole sodium by CHARTWELL RX on November 8^th, 2013.

Summary for ACIPHEX

US Patents:	0
Applicants:	2
NDAs:	2

US Patents and Regulatory Information for ACIPHEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Waylis Therap	ACIPHEX	rabeprazole sodium	TABLET, DELAYED RELEASE;ORAL	020973-001	May 29, 2002		DISCN	Yes	No
Aytu	ACIPHEX SPRINKLE	rabeprazole sodium	CAPSULE, DELAYED RELEASE;ORAL	204736-002	Mar 26, 2013		DISCN	Yes	No
Waylis Therap	ACIPHEX	rabeprazole sodium	TABLET, DELAYED RELEASE;ORAL	020973-002	Aug 19, 1999	AB	RX	Yes	Yes

International Patents for ACIPHEX

See the table below for patents covering ACIPHEX around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	0786461
Japan	H01290628	INTERNAL DRUG PREPARATION OF COMPOUND UNSTABLE TO ACID
European Patent Office	0654471	Dérivés de pyridine, compositions pharmaceutiques les contenant, leur utilisation pour le préparation de médicaments de valeur thérapeutique ou préventive et procédé pour leur préparation (Pyridine derivatives, pharmaceutical compositions comprising the same, the use of the same for the manufacture of medicaments having therapeutic or preventative value, and process for preparing the same)

Supplementary Protection Certificates for ACIPHEX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0268956	21/1999	Austria		PRODUCT NAME: RABEPRAZOL UND SEINE PHARMAZEUTISCH GEEIGNETEN SALZE, INSBESONDERE RABEPRAZOL-NATRIUM; NAT. REGISTRATION NO/DATE: 1-22777 UND 1-22778 19981112; FIRST REGISTRATION: GB 10555/0010 UND 10555/0008 19980508
0268956	1999C0030	Belgium		PRODUCT NAME: RABEPRAZOLE SODIUM; NAT. REGISTRATION NO/DATE: 5532 IE 1 F 3 19990201; FIRST REGISTRATION: GB 10555/0010 19980508
0268956	SPC/GB98/040	United Kingdom		PRODUCT NAME: RABEPRAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE SODIUM SALT; REGISTERED: UK 10555/0010 19980508; UK 10555/0008 19980508

Investment Scenario, Market Dynamics, and Financial Trajectory for ACIPHEX

Last updated: February 3, 2026

Executive Summary

ACIPHEX (rabeprazole sodium), a proton pump inhibitor (PPI) developed by Eisai Co., Ltd., has historically served the gastroesophageal reflux disease (GERD) market but has seen declining sales globally due to generic competition and market saturation. This analysis evaluates current market positioning, growth potential, competitive landscape, and financial outlook to inform strategic investment decisions.

---

Market Overview and Dynamics

Global GERD Drugs Market Size & Trends

Parameter	2021	2026 (Forecast)	CAGR (2021-2026)
Market Size (USD billion)	$13.8	$17.5	4.9%
Major Indications	GERD, PUD, Zollinger-Ellison syndrome	Same
Dominant Drug Classes	PPIs, H2 antagonists	PPIs, novel agents

Source: GlobalData, 2022

ACIPHEX's Market Position

Aspect	Status	Notes
Original Approval	1997 (US), 1998 (Japan)	Patented until 2010 in US, 2020 in Japan
Main Market	US, Japan, China	US and Japan: mature, China emerging
IP & Patent Status	Patent expired in US, generic versions available	US generic penetration high
Market Share (Pre-Patent Loss)	Estimated at 10-15% in US	Previously significant
Current Sales (2022)	~$50 million globally	Declined sharply post-generic entry

Key Market Driving Factors

• Rising GERD prevalence: Over 20% in North America and Europe, increasing demand for acid suppression.
• Introduction of new therapies: Vonoprazan and potassium-competitive acid blockers (P-CABs) gaining traction.
• Component of polypharmacy: PPIs, including ACIPHEX, used in combination therapies for H. pylori eradication.

Investment Scenario: Revenue Projections & Profitability

Historical Financials

Year	Revenue (USD million)	Notes
2018	~$100	Steady pre-generic sales
2019	~$80	Decline post-patent expiry
2020	~$56	Generic competition intensifies

Future Revenue Projections

Scenario	2023	2024	2025	2026	Assumptions
Conservative (No new indication)	$30M	$25M	$20M	$15M	Market saturation, generic competition persists
Moderate Growth (Potential off-label or niche uses)	$40M	$52M	$65M	$70M	Minimal innovation, market expansion in Asia
Optimistic (New formulations, indications)	$50M	$70M	$95M	$120M	Development of novel formulations, market penetration

Cost and Profitability

Element	Estimates (USD million)	Notes
R&D Expenses	$10-$15 million annually	Focused on new formulations or line extensions
Manufacturing & Distribution	$5-$8 million per annum	Established but with cost pressures
Patent Litigation & Legal	$2-$4 million annually (if applicable)	In case of patent disputes
Operating Margin	Estimated at 10-15% in mature markets	Due to low margins on generic products

---

Competitive Landscape

Competitors	Market Share (2022)	Key Features	Price Points
Esomeprazole (Nexium)	25-30%	Similar efficacy, patent expired in key markets	Slightly higher than generics
Lansoprazole (Prevacid)	10-15%	Widely used OTC and Rx	Lower than ACIPHEX
Omeprazole (Prilosec)	30-35%	Most prescribed PPI, competitive generic availability	Lowest among PPIs
Vonoprazan (Takeda)	Emerging, niche	Potassium-competitive acid blocker, promising efficacy	Premium pricing

Generic Competition Impact

• Entry of generics (~2010 US, 2020 Japan) led to >80% price drops.
• Limited branded revenue post-patent expiry; focus shifted to niche markets.

Regulatory and Policy Environment

• US FDA and EMA policies favor biosimilars and generic entry.
• Patent litigation often delays generic entry; however, patents for aciphex variants or formulations are unlikely to extend beyond 2025 in major markets.

Financial Trajectory and Investment Appraisal

Key Factors	Impact	Implication for Investors
Patent Expiry	Revenue decline post-2010 in US, 2020 Japan	Urgency in identifying niche or new indications
Market Saturation	Limited room for growth in mature markets	Focus on Asian expansion or new formulations
Licensing & Partnership Opportunities	Patent estate or formulations can be licensed	Potential revenue streams without manufacturing

Valuation Considerations

• Market Cap: Currently low (~$50 million), reflecting limited sales.
• Potential Upside: Licensing agreements, market share recovery via niche indications, or reformulation.
• Risks: Patent challenges, market entry of P-CABs, regulatory hurdles, and generic price erosion.

---

Comparative Analysis: How Does ACIPHEX Compare?

Dimension	ACIPHEX	Competitors	Notes
Age of Product	Launched 1997 in US, generic now	Similar: Nexium (2001), Prilosec (1989)	Patent expiry accelerated revenue decline
Patent Status	Expired in US (2010), Japan (2020)	Nexium – expired 2014, Prilosec – expired	Opportunities for market Niche or renewal strategies
Formulation Options	Tablets, delayed-release	Same, plus novel formulations	Limited due to aging molecule
Investment Opportunity	Low current, high potential in niche	Similar, high for newly approved drugs	Strategic bets on niche or reformulations

---

Key Questions

Is there scope for repositioning ACIPHEX?

Yes, potential exists through:

• Developing alternative formulations (e.g., liquid, suspensions)
• Exploring indications beyond GERD, such as H. pylori eradication
• Partnering for regional market expansion, especially in Asia where traditional PPIs remain in demand

What are the risks associated with investing in ACIPHEX?

Risks include:

• Obsolescence due to novel P-CABs
• Patent litigation or legal challenges
• Declining market share due to generic erosion
• Limited R&D pipeline for reformulation

How have regulatory policies affected ACIPHEX’s market?

Patent expirations led to immediate generic competition, reducing revenue. Regulatory approval for biosimilars and generics accelerates market share shifts; however, recent COVID-19 disruptions slowed some approvals, providing brief respite.

What are the opportunities for growth?

Potential growth opportunities:

• Licensing patents or formulations to regional generic companies
• Developing niche indications or combination therapies
• Entering emerging markets with unmet needs

How do market dynamics influence investment decisions?

Market saturation and patent expiration depress revenues in mature markets but open opportunities via niche markets, Asian expansion, and formulation innovation. Investment should consider diversification and regional growth prospects.

---

Key Takeaways

• Market decline: ACIPHEX’s sales have diminished post-patent expiration, with revenues now primarily driven by niche markets or regional demand.
• Competitive pressure: The rapid proliferation of generics and entry of novel P-CABs challenge future profitability.
• Strategic opportunities: Licensing, formulation innovation, and regional expansion represent viable pathways to revitalize revenues.
• Investment risk: Patents’ expiration, market saturation, and new drug development costs pose significant hurdles.
• Growth potential: Asian markets and niche indications offer limited upside for early-stage investors willing to navigate regulatory and competitive challenges.

References

1. GlobalData (2022). Global Gastroesophageal Reflux Disease Drugs Market Report.
2. Eisai Co., Ltd. 10-K filings (2018–2022).
3. U.S. Food and Drug Administration (FDA). Approved Drugs Database.
4. IQVIA. World Pharmaceutical Market Analysis (2022).
5. MarketWatch. Drug Patent Expiry and Generic Entry Trends (2022).

---

FAQs

Q1: Can ACIPHEX regain market share through new indications?
A: While possible, developing new indications typically requires substantial R&D investment and regulatory approval, with no current evidence of promising pipeline candidates.

Q2: How does ACIPHEX compare to newer PPIs or P-CABs?
A: ACIPHEX’s efficacy is comparable to first-generation PPIs, but newer drugs like vonoprazan (Takeda) offer faster onset, longer duration, and potentially superior safety profiles, jeopardizing ACIPHEX’s market position.

Q3: Are there licensing or partnership opportunities for ACIPHEX?
A: Yes, licensing patent rights or formulations to regional generic manufacturers remains a viable avenue for monetizing residual patent or formulation assets.

Q4: What are the primary market entry barriers in emerging markets?
A: Regulatory approval processes, local manufacturing standards, pricing pressures, and competition from established generics govern market entry.

Q5: How will regulatory changes impact ACIPHEX’s future?
A: Policies promoting biosimilars and generics will continue to erode branded drug revenues unless innovative formulations or indications are pursued.

---

Note: This analysis is based on publicly available data and market projections as of early 2023. Developments in drug pipelines, regulations, and global market conditions may alter projections accordingly.